Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
For HIV-infected individuals with highly resistant viruses, higher drug levels may be
required to block the virus. This study investigates that concept by comparing the efficacy
of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a
combination of fosamprenavir (increased dose)/lopinavir/ritonavir.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fosamprenavir HIV Protease Inhibitors Lopinavir Protease Inhibitors Ritonavir